WO2007112052A3 - Formulations and methods for vascular permeability-related diseases or conditions - Google Patents

Formulations and methods for vascular permeability-related diseases or conditions Download PDF

Info

Publication number
WO2007112052A3
WO2007112052A3 PCT/US2007/007353 US2007007353W WO2007112052A3 WO 2007112052 A3 WO2007112052 A3 WO 2007112052A3 US 2007007353 W US2007007353 W US 2007007353W WO 2007112052 A3 WO2007112052 A3 WO 2007112052A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
methods
vascular permeability
conditions
related diseases
Prior art date
Application number
PCT/US2007/007353
Other languages
French (fr)
Other versions
WO2007112052A2 (en
Inventor
David M Kleinman
Thierry Nivaggioli
Mary Gerritsen
David A Weber
Original Assignee
Macusight Inc
David M Kleinman
Thierry Nivaggioli
Mary Gerritsen
David A Weber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK07753937.7T priority Critical patent/DK2001466T3/en
Priority to PL07753937T priority patent/PL2001466T3/en
Priority to AU2007230964A priority patent/AU2007230964B2/en
Priority to CN2007800099462A priority patent/CN101443004B/en
Priority to ES07753937.7T priority patent/ES2563288T3/en
Priority to EP07753937.7A priority patent/EP2001466B1/en
Priority to CA2645488A priority patent/CA2645488C/en
Priority to KR1020147022952A priority patent/KR101520408B1/en
Application filed by Macusight Inc, David M Kleinman, Thierry Nivaggioli, Mary Gerritsen, David A Weber filed Critical Macusight Inc
Priority to JP2009501599A priority patent/JP5506378B2/en
Priority to BRPI0709016-1A priority patent/BRPI0709016A2/en
Publication of WO2007112052A2 publication Critical patent/WO2007112052A2/en
Publication of WO2007112052A3 publication Critical patent/WO2007112052A3/en
Priority to KR1020087025772A priority patent/KR101468941B1/en
Priority to HK09105389.9A priority patent/HK1126427A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability.
PCT/US2007/007353 2006-03-23 2007-03-23 Formulations and methods for vascular permeability-related diseases or conditions WO2007112052A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA2645488A CA2645488C (en) 2006-03-23 2007-03-23 Formulations comprising rapamycin and methods using same for vascular permeability-related diseases or conditions
AU2007230964A AU2007230964B2 (en) 2006-03-23 2007-03-23 Formulations and methods for vascular permeability-related diseases or conditions
CN2007800099462A CN101443004B (en) 2006-03-23 2007-03-23 Formulations and methods for vascular permeability-related diseases or conditions
ES07753937.7T ES2563288T3 (en) 2006-03-23 2007-03-23 Rapamycin in low doses for the treatment of diseases related to vascular permeability
EP07753937.7A EP2001466B1 (en) 2006-03-23 2007-03-23 Low-dose rapamycin for the treatment of vascular permeability-related diseases
DK07753937.7T DK2001466T3 (en) 2006-03-23 2007-03-23 LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
KR1020147022952A KR101520408B1 (en) 2006-03-23 2007-03-23 Formulations and methods for vascular permeability-related diseases or conditions
PL07753937T PL2001466T3 (en) 2006-03-23 2007-03-23 Low-dose rapamycin for the treatment of vascular permeability-related diseases
JP2009501599A JP5506378B2 (en) 2006-03-23 2007-03-23 Formulations and methods for diseases or conditions associated with vascular permeability
BRPI0709016-1A BRPI0709016A2 (en) 2006-03-23 2007-03-23 formulations and methods for diseases or conditions related to vascular permeability
KR1020087025772A KR101468941B1 (en) 2006-03-23 2008-10-22 - formulations and methods for vascular permeability-related diseases or conditions
HK09105389.9A HK1126427A1 (en) 2006-03-23 2009-06-16 Low-dose rapamycin for the treatment of vascular permeability-related diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78581406P 2006-03-23 2006-03-23
US60/785,814 2006-03-23

Publications (2)

Publication Number Publication Date
WO2007112052A2 WO2007112052A2 (en) 2007-10-04
WO2007112052A3 true WO2007112052A3 (en) 2008-04-03

Family

ID=38541710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/007353 WO2007112052A2 (en) 2006-03-23 2007-03-23 Formulations and methods for vascular permeability-related diseases or conditions

Country Status (13)

Country Link
US (3) US8222271B2 (en)
EP (1) EP2001466B1 (en)
JP (2) JP5506378B2 (en)
KR (2) KR101520408B1 (en)
CN (2) CN101443004B (en)
AU (1) AU2007230964B2 (en)
BR (1) BRPI0709016A2 (en)
CA (1) CA2645488C (en)
DK (1) DK2001466T3 (en)
ES (1) ES2563288T3 (en)
HK (1) HK1126427A1 (en)
PL (1) PL2001466T3 (en)
WO (1) WO2007112052A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR101387456B1 (en) 2005-02-09 2014-04-21 산텐 세이야꾸 가부시키가이샤 Liquid formulations for treatment of diseases or conditions
KR20070121754A (en) * 2005-03-21 2007-12-27 마커사이트, 인코포레이티드 Drug delivery systems for treatment of diseases or conditions
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
US20100040669A1 (en) * 2008-08-12 2010-02-18 Higuchi John W Non-Invasive Ocular Delivery of Rapamycin
WO2011071535A2 (en) * 2009-12-11 2011-06-16 Mount Sinai School Of Medicine Of New York University Compositions and methods for inhibiting human host cell factors required for influenza virus replication
WO2011135400A1 (en) 2010-04-30 2011-11-03 Indian Institute Of Technology Bombay Nanoparticulate in-situ gels as vitreous humor substitutes for ocular diseases
FI3821891T3 (en) 2011-05-02 2023-08-24 Univ Leland Stanford Junior Use of fk506 for the treatment of pulmonary arterial hypertension
CN102274219A (en) * 2011-06-27 2011-12-14 苏州大学附属第一医院 Application of rapamycin to treating early brain injury after subarachnoid hemorrhage
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
AU2014348657A1 (en) * 2013-11-13 2016-05-19 Novartis Ag mTOR inhibitors for enhancing the immune response
CA2975879A1 (en) 2015-02-05 2016-08-11 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of edema
WO2016185443A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
KR20180053340A (en) 2015-09-18 2018-05-21 산텐 세이야꾸 가부시키가이샤 Prevention or treatment of corneal myositis
US10695326B2 (en) 2015-09-24 2020-06-30 Drexel University Compositions and methods for treating or preventing dermal disorders
EP3463349B1 (en) 2016-05-25 2021-08-04 Santen Pharmaceutical Co., Ltd. Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
AU2017290593A1 (en) 2016-06-27 2019-01-03 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
CA2972296A1 (en) 2016-06-30 2017-12-30 Durect Corporation Depot formulations
CN106248947A (en) * 2016-07-21 2016-12-21 中国人民解放军军事医学科学院基础医学研究所 A kind of mammal high altitude cerebral adema biomarker and application thereof
BR112019010470A2 (en) 2016-11-23 2019-09-10 Novartis Ag immune response enhancement methods with everolimus, dactolisib or both
US11413280B2 (en) 2017-05-19 2022-08-16 The Board Of Trustees Of The Leland Stanford Junior University Enzastaurin and fragile histidine triad (FHIT)-increasing agents for the treatment of pulmonary hypertension
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
JP2021519337A (en) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Cereblon binder for the degradation of Ikaras
JP2021535112A (en) 2018-08-20 2021-12-16 アキリオン ファーマシューティカルズ，インコーポレーテッド Pharmaceutical compounds for the treatment of medical disorders of complement D factor
EP3866773A4 (en) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
EP3932487A4 (en) * 2019-02-27 2022-11-02 Osaka University External preparation for vascular abnormality treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
WO2005094279A2 (en) * 2004-03-25 2005-10-13 The Rothberg Institute For Childhood Diseases Immortalized human tuberous sclerosis null angiomyolipoma cell and method of use thereof
WO2006039336A2 (en) * 2004-10-01 2006-04-13 Ramscor, Inc. Conveniently implantable sustained release drug compositions

Family Cites Families (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3828777A (en) 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US3914402A (en) 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
US3926188A (en) 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
FR2382240A1 (en) 1977-03-03 1978-09-29 Mouls Pierre Ophthalmic solution diffusion equipment - delivers fine mist to cornea indirectly using cup with baffles
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
AU543727B2 (en) 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
IT1141715B (en) 1980-06-06 1986-10-08 Sadepan Chimica Spa UREA-FORMALDEHYDE RESIN BASED ADHESIVE WITH CALCIUM AND / OR AMMONIUM LIGNINSULPHONATE, UREA FORMALDEHYDE RESIN MODIFIED WITH CALCIUM LIGNINSULPHONATE AND / OR AMMONIUM AND PRODUCTION METHOD OF THE SAME, FOR THE PREPARATION OF WOOD PANELS
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US5322691A (en) * 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
EP0391909B1 (en) 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
US4946450A (en) 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5883082A (en) * 1990-08-14 1999-03-16 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
JPH04230389A (en) 1990-07-16 1992-08-19 American Home Prod Corp Rapamycin derivative
DE4022553A1 (en) 1990-07-16 1992-01-23 Hund Helmut Gmbh Medical contact lens - with recess contg. therapeutically or diagnostically active substance
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
PT98990A (en) 1990-09-19 1992-08-31 American Home Prod PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN
US5290892A (en) * 1990-11-07 1994-03-01 Nestle S.A. Flexible intraocular lenses made from high refractive index polymers
CA2054983A1 (en) 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
EP0581959B1 (en) * 1991-04-26 2001-01-17 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for eye diseases
US5565560A (en) 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5120727A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5120725A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5457111A (en) 1991-09-05 1995-10-10 Abbott Laboratories Macrocyclic immunomodulators
US5192802A (en) * 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
PH30923A (en) * 1992-03-30 1997-12-23 American Home Prod Rapamycin formulation for iv injection.
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
FR2690846B1 (en) * 1992-05-05 1995-07-07 Aiache Jean Marc GALENIC FORM FOR EYE ADMINISTRATION AND METHOD OF PREPARATION.
WO1994005257A1 (en) 1992-09-08 1994-03-17 Allergan, Inc. Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
DK0669127T3 (en) * 1992-11-18 1999-12-06 Fujisawa Pharmaceutical Co Prolonged action pharmaceutical preparation
JPH08507789A (en) 1993-03-17 1996-08-20 アボツト・ラボラトリーズ Macrocyclic amide and urea immunomodulators
GB2278780B (en) 1993-05-27 1998-10-14 Sandoz Ltd Macrolide formulations
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
DK0797988T3 (en) * 1993-07-19 2009-05-11 Univ British Columbia Anti-angiogenic compositions and methods for their use
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
IL111004A (en) 1993-09-30 1998-06-15 American Home Prod Oral rapamycin formulations
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
EP0729471A1 (en) 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
CN1046944C (en) * 1993-12-17 1999-12-01 山道士有限公司 Rapamycin derivatives useful as immunosuppressants
US5788687A (en) 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5773021A (en) * 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
JPH09511507A (en) 1994-04-04 1997-11-18 フリーマン，ウイリアム・アール Use of phosphonyl methoxyalkyl nucleosides to treat elevated intraocular pressure
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5621108A (en) * 1994-12-05 1997-04-15 Trustees Of The University Of Pennsylvania Processes and intermediates for preparing macrocycles
US5725493A (en) * 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
CN1283324C (en) 1995-05-14 2006-11-08 奥普通诺尔有限公司 Intraocular implant, delivery device, and method of implantation
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5614547A (en) * 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
BE1009856A5 (en) 1995-07-14 1997-10-07 Sandoz Sa Pharmaceutical composition in the form of a solid release including macrolide and a vehicle.
JPH0930966A (en) 1995-07-24 1997-02-04 Gakuzo Tamura New pharmaceutical preparation for eye
ATE254450T1 (en) 1995-09-19 2003-12-15 Fujisawa Pharmaceutical Co AEROSOL COMPOSITIONS
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
AU712015B2 (en) 1995-10-31 1999-10-28 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
DE69733338T2 (en) 1996-02-13 2006-03-16 G.D. Searle & Co., Chicago PREPARATIONS, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIEN B4 RECEPTOR ANTAGONIST
US5743274A (en) 1996-03-18 1998-04-28 Peyman; Gholam A. Macular bandage for use in the treatment of subretinal neovascular members
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
JP3309175B2 (en) 1996-03-25 2002-07-29 参天製薬株式会社 Scleral plug containing proteinaceous drug
JPH09315954A (en) 1996-05-30 1997-12-09 Kita:Kk Medicine for preventing opacity of ocular tissue after ophthalmic operation
GB9710962D0 (en) * 1997-05-28 1997-07-23 Univ Cambridge Tech Polyketides and their synthesis
RU2123314C1 (en) 1996-06-27 1998-12-20 Павлова Татьяна Вячеславовна Method of placing irrigation system into tenon's space
ATE340586T1 (en) 1996-07-30 2006-10-15 Novartis Pharma Gmbh PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TRANSPLANT REJECTION AND AUTOIMMUNE OR INFLAMMATORY CONDITIONS
US6007510A (en) 1996-10-25 1999-12-28 Anamed, Inc. Implantable devices and methods for controlling the flow of fluids within the body
US6142969A (en) 1996-10-25 2000-11-07 Anamed, Inc. Sutureless implantable device and method for treatment of glaucoma
AUPO427196A0 (en) 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
JPH10218787A (en) 1997-02-06 1998-08-18 Akio Okamoto Ophthalmic composition based on neurotrophic factor
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
ES2232005T3 (en) 1997-08-11 2005-05-16 Allergan, Inc. BIODEGRADABLE STERILE IMPLANT DEVICE CONTAINING RETINOID WITH IMPROVED BIOCOMPATIBILITY AND PREPARATION METHOD.
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20060198867A1 (en) 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US20030190286A1 (en) 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
KR100883149B1 (en) 1997-10-22 2009-02-10 젠스 포니카우 Use of antifungal agents for the topical treatment of fungus-induced mucositis
AR043071A1 (en) 1997-10-31 2005-07-20 Abbott Lab USE OF MACROLIDES FOR THE TREATMENT OF CANCER AND MACULAR DEGENERATION AND A PHARMACEUTICAL COMPOSITION
CZ287497B6 (en) 1997-12-30 2000-12-13 Galena, A. S. Topic eye preparations containing immunosuppressive substances
AU2337599A (en) 1998-01-23 1999-08-09 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
DE19810655A1 (en) 1998-03-12 1999-09-16 Univ Eberhard Karls Pharmaceutical composition containing cyclosporin A suitable for topical administration for treating disorders of skin, mucosa and eyes
EP1061913B1 (en) 1998-03-13 2007-06-27 The Johns Hopkins University School Of Medicine The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy
AU3980499A (en) 1998-05-11 1999-11-29 Endowment for Research in Human Biology, Inc., The Use of neomycin for treating angiogenesis-related diseases
US6399629B1 (en) * 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
NZ509328A (en) 1998-07-24 2002-11-26 Jago Res A Medicinal aerosol formulations
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
US6632836B1 (en) 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
ES2217819T3 (en) 1998-11-17 2004-11-01 Ortho-Mcneil Pharmaceutical, Inc. ANTI-CONVULSIVE DERIVATIVES FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDERS.
GB9826882D0 (en) 1998-12-07 1999-01-27 Novartis Ag Organic compounds
US6399655B1 (en) 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
HUP0201972A3 (en) 1998-12-23 2005-06-28 G D Searle Llc Chicago Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
US6864232B1 (en) * 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
MXPA01006449A (en) 1998-12-24 2002-04-24 R Tech Ueno Ltd Agent for treating visual cell function disorder.
CA2358296A1 (en) 1999-01-05 2000-07-13 Anthony P. Adamis Targeted transscleral controlled release drug delivery to the retina and choroid
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
MXPA01010988A (en) 1999-04-30 2004-04-21 Sucampo Ag Use of macrolide compounds for the treatment of dry eye.
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
JP2001064198A (en) 1999-08-24 2001-03-13 Teika Seiyaku Kk Therapeutic agent for corneal disease
AU7452900A (en) 1999-10-18 2001-04-30 Fujisawa Pharmaceutical Co., Ltd. Method for producing liposome preparation
ATE283013T1 (en) 1999-10-21 2004-12-15 Alcon Inc MEDICATION DELIVERY DEVICE
CA2383572C (en) 1999-10-21 2007-12-11 Alcon Universal Ltd. Sub-tenon drug delivery
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
WO2001030386A1 (en) 1999-10-22 2001-05-03 Biogen, Inc. Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye
EP1225879A2 (en) * 1999-10-22 2002-07-31 Orbon Corporation Ophthalmic formulation of dopamine antagonists
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6670168B1 (en) 1999-10-29 2003-12-30 Kosan Bioscience, Inc. Recombinant Streptomyces hygroscopicus host cells that produce 17-desmethylrapamycin
RU2149615C1 (en) 1999-11-10 2000-05-27 Нестеров Аркадий Павлович Method for introducing drugs in treating posterior eye segment diseases
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
JP2003518485A (en) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク Pharmaceutical composition giving improved drug concentration
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
US6489335B2 (en) 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
DK1142566T3 (en) 2000-04-07 2004-02-09 Medidom Lab Ophthalmological formulations based on cyclosporine, hyaluronic acid and polysorbate
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
FR2809619B1 (en) 2000-06-06 2004-09-24 Pharmatop NOVEL AQUEOUS FORMULATIONS OF OXIDATION-SENSITIVE ACTIVE INGREDIENTS AND PROCESS FOR OBTAINING THEM
CN1127955C (en) 2000-07-07 2003-11-19 中山医科大学中山眼科中心 Medicine for treating immune relative disease of anterior chamber and surface of eye
ATE547080T1 (en) * 2000-08-30 2012-03-15 Univ Johns Hopkins DEVICES FOR INTRAOCULAR DRUG DELIVERY
CN1204919C (en) 2000-08-30 2005-06-08 中国科学院化学研究所 Long-acting intra-ocular release system of cyclosporin
AU2001296558A1 (en) 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US20050084514A1 (en) * 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
ES2250504T3 (en) * 2000-11-29 2006-04-16 Allergan Inc. PREVENTION OF REJECTION OF GRAFT IN THE EYE.
DE60130928T2 (en) 2001-01-03 2008-07-17 Bausch & Lomb Inc. DEVICE FOR DELAYED ACTIVE INGREDIENT RELIEF WITH COATED MEDICATION CORE
NZ527046A (en) 2001-01-16 2005-06-24 Vascular Therapies Llc A flexible cylindrical matrix material, preferably collagen with an antiproliferative agent preferably rapamycin dispersed throughout for implantation to be in contact with a vascular structure
US7181287B2 (en) * 2001-02-13 2007-02-20 Second Sight Medical Products, Inc. Implantable drug delivery device
PT3351246T (en) 2001-02-19 2019-06-07 Novartis Pharma Ag Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
AR033151A1 (en) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc AGENT FOR THE TOPICAL OPHTHALMIC TREATMENT OF OCULAR INFLAMMATORY DISEASES
JP2004536631A (en) * 2001-05-03 2004-12-09 マサチューセッツ・アイ・アンド・イア・インファーマリー Implantable drug delivery device and use thereof
JP2002332225A (en) 2001-05-09 2002-11-22 Lion Corp Ophthalmic composition
JP2003009899A (en) * 2001-05-28 2003-01-14 New Industry Research Organization Method for screening compound
EP1404297B1 (en) 2001-06-12 2011-04-27 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
US7034037B2 (en) * 2001-06-29 2006-04-25 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin
WO2003004098A1 (en) * 2001-07-06 2003-01-16 Sucampo Ag Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
AR035293A1 (en) 2001-08-23 2004-05-05 Novartis Ag OPHTHALMIC COMPOSITION.
US6812220B2 (en) 2001-08-29 2004-11-02 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US6656460B2 (en) 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
PL371929A1 (en) 2001-11-09 2005-07-11 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
US6663880B1 (en) * 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
EP1455810B1 (en) 2001-12-14 2007-06-13 Jagotec Ag Pharmaceutical formulation comprising cyclosporin and use thereof
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds
DE60313299T2 (en) 2002-03-01 2008-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Self-regulating systems for the delivery of TAXOIDS
AU2003209475A1 (en) 2002-03-07 2003-09-16 Vectura Limited Fast melt multiparticulate formulations for oral delivery
CN1456350A (en) 2002-05-10 2003-11-19 刘继东 Eye cyclosporin gel
US20040057958A1 (en) * 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
US7026374B2 (en) * 2002-06-25 2006-04-11 Aruna Nathan Injectable microdispersions for medical applications
DE60315723T2 (en) 2002-07-16 2008-06-19 Biotica Technology Ltd. Production of polyketides and other natural products
UA82328C2 (en) 2002-07-30 2008-04-10 Уайт Parenteral formulations of rapamycin hydroxyester (variants) and a method for its preparation
CA2495103A1 (en) 2002-08-09 2004-02-19 Sucampo Pharmaceuticals, Inc. Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases
EP1539157B1 (en) 2002-09-18 2013-08-21 Trustees Of The University Of Pennsylvania Rapamycin for use in inhibiting or preventing choroidal neovascularization
US20050143363A1 (en) 2002-09-29 2005-06-30 Innorx, Inc. Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AU2003293529A1 (en) 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
US20040198763A1 (en) 2003-01-16 2004-10-07 Sucampo Ag Method of treating dry eye with a macrolide compound
DK1599573T3 (en) 2003-02-17 2013-07-08 Cold Spring Harbor Lab Model to study the role of genes in tumor resistance to chemotherapy
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
WO2004096261A1 (en) 2003-05-02 2004-11-11 Arturo Jimenez Bayardo Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
ES2315680T3 (en) * 2003-06-26 2009-04-01 Psivida Inc. IN SITU GELIFICATION PHARMACY DISTRIBUTION SYSTEM.
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
EP1510206A1 (en) 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
AU2004274026A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US20050181018A1 (en) 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7402399B2 (en) 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
CA2536188A1 (en) 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
WO2006053007A2 (en) 2004-11-09 2006-05-18 Angiotech Biocoatings Corp. Antimicrobial needle coating for extended infusion
WO2005051452A2 (en) 2003-11-20 2005-06-09 Angiotech International Ag Polymer compositions and methods for their use
US7186518B2 (en) * 2003-11-21 2007-03-06 Dade Behring Inc. Method and composition useful for determining FK 506
US8529939B2 (en) 2003-12-08 2013-09-10 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
JP2007523911A (en) 2004-02-26 2007-08-23 アドバンスト アキュラー システムズ リミテッド Tetracycline derivatives for the treatment of ocular lesions
US7846940B2 (en) 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
CA2562356A1 (en) 2004-04-08 2005-10-27 Retmed Pty Ltd Treatment of ophthalmic conditions with mineralcorticoids
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20050250804A1 (en) 2004-05-06 2005-11-10 Glenmark Pharmaceuticals Limited Pharmaceutical gel formulations
US20060018948A1 (en) 2004-06-24 2006-01-26 Guire Patrick E Biodegradable implantable medical devices, methods and systems
WO2006002365A2 (en) 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
US20060024350A1 (en) * 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
CA2571899A1 (en) * 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US20060110428A1 (en) 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
WO2006020755A2 (en) 2004-08-10 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
WO2006023130A2 (en) * 2004-08-12 2006-03-02 Surmodics, Inc. Biodegradable controlled release bioactive agent delivery device
AR050374A1 (en) 2004-08-20 2006-10-18 Wyeth Corp RAFAMPICINE POLYMORPHIC FORM
CA2578245C (en) 2004-08-27 2013-10-29 Cordis Corporation Solvent free amorphous rapamycin
CA2582374A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
KR101387456B1 (en) 2005-02-09 2014-04-21 산텐 세이야꾸 가부시키가이샤 Liquid formulations for treatment of diseases or conditions
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
KR20070121754A (en) 2005-03-21 2007-12-27 마커사이트, 인코포레이티드 Drug delivery systems for treatment of diseases or conditions
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
WO2006110487A1 (en) 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants for subretinal delivery
US20100087474A1 (en) 2005-04-27 2010-04-08 University Of Florida Materials and methods for enhanced degradation of mutant proteins associated with human disease
US20060247265A1 (en) 2005-04-28 2006-11-02 Clackson Timothy P Therapies for treating disorders of the eye
JP2009500297A (en) 2005-06-08 2009-01-08 セントカー・インコーポレーテツド Cell therapy for ocular degeneration
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
WO2007047626A1 (en) 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
DE102006051512A1 (en) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmaceutical drug compositions with cyclosporin
ATE446087T1 (en) 2006-01-23 2009-11-15 Yissum Res Dev Co MICROBEADS WITH NANOCAPSULES CONTAINING A LIPOPHILIC MEDICINAL
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
AU2007219981B2 (en) 2006-02-28 2013-11-07 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
WO2005094279A2 (en) * 2004-03-25 2005-10-13 The Rothberg Institute For Childhood Diseases Immortalized human tuberous sclerosis null angiomyolipoma cell and method of use thereof
WO2006039336A2 (en) * 2004-10-01 2006-04-13 Ramscor, Inc. Conveniently implantable sustained release drug compositions

Also Published As

Publication number Publication date
KR101520408B1 (en) 2015-05-14
CN103127100A (en) 2013-06-05
EP2001466A2 (en) 2008-12-17
CA2645488A1 (en) 2007-10-04
KR20140108342A (en) 2014-09-05
US20070265294A1 (en) 2007-11-15
JP5506378B2 (en) 2014-05-28
PL2001466T3 (en) 2016-06-30
US8222271B2 (en) 2012-07-17
EP2001466B1 (en) 2016-01-06
US9452156B2 (en) 2016-09-27
DK2001466T3 (en) 2016-02-29
WO2007112052A2 (en) 2007-10-04
AU2007230964A1 (en) 2007-10-04
KR20090013761A (en) 2009-02-05
JP2013237712A (en) 2013-11-28
BRPI0709016A2 (en) 2011-06-21
CA2645488C (en) 2014-09-02
CN101443004B (en) 2013-03-06
ES2563288T3 (en) 2016-03-14
US20120329759A1 (en) 2012-12-27
HK1126427A1 (en) 2009-09-04
KR101468941B1 (en) 2014-12-04
US20150265581A1 (en) 2015-09-24
US8486960B2 (en) 2013-07-16
JP2009530406A (en) 2009-08-27
AU2007230964B2 (en) 2012-07-19
JP5860013B2 (en) 2016-02-16
CN101443004A (en) 2009-05-27

Similar Documents

Publication Publication Date Title
WO2007112052A3 (en) Formulations and methods for vascular permeability-related diseases or conditions
WO2006044775A3 (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2010126626A3 (en) Dual mechanism inhibitors for the treatment of disease
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2007016578A3 (en) Prenylflavonoid formulations
WO2007089611A3 (en) Compositions and their uses directed to huntingtin
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
WO2006124874A3 (en) Inhibitors of b-raf kinase
EP2192901A4 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2006113919A3 (en) Aryl alkyl acid derivatives for and use thereof
WO2008067121A3 (en) Methods of treating cognitive impairment and dementia
WO2010017541A3 (en) Compositions and methods for treatment of neurodegenerative disease
WO2007101247A3 (en) Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
WO2007024971A3 (en) Hedgehog pathway antagonists to treat disease
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2008017346A3 (en) Ascorbic acid derivatives, use thereof for the functionalization of matrices
WO2009111633A3 (en) Mercaptan and seleno-mercaptan compounds and methods of using them
WO2009025926A3 (en) Nanoparticle-coated medical devices and formulations for treating vascular disease
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2008073463A3 (en) Methods and compositions for treating and monitoring treatment of il-13-associated disorders
WO2008149353A3 (en) Telomerase activating compounds and methods of use thereof
WO2007121125A3 (en) Hcv inhibitors
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
WO2007146335A3 (en) Compounds and compositions for treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2645488

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007230964

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200780009946.2

Country of ref document: CN

Ref document number: 2009501599

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007230964

Country of ref document: AU

Date of ref document: 20070323

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087025772

Country of ref document: KR

Ref document number: 2007753937

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 8932/DELNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: PI0709016

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080922